I'm curious to see how high J&J prices abiraterone after approval. I've heard chatter of a whopping $100,000-plus price tag. If J&J goes there, Dendreon will no longer wear the black hat as the prostate cancer drug pricing scoundrel.
And there's certainly recent precedent for stratospheric cancer drug pricing outside of Provenge -- Bristol-Myers Squibb (BMY) priced its melanoma immunotherapy Yervoy at $120,000 for a four-course treatment.
Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.>To submit a news tip, send an email to: email@example.com.